Population-specific genetic insights are reshaping how we approach disease prevention and healthspan optimization, particularly for underrepresented Asian populations who comprise 60% of the global population yet remain significantly underrepresented in genomic databases. This demographic gap has historically limited the effectiveness of precision medicine approaches developed primarily from European genetic data. Singapore's systematic population health research is uncovering genetic variants unique to Asian populations that influence disease susceptibility, drug metabolism, and aging trajectories. These discoveries are enabling the development of ethnicity-specific risk prediction models and therapeutic interventions that account for genetic diversity in metabolism, immune responses, and age-related disease progression. The research addresses critical gaps in pharmacogenomics, where Asian populations often show different drug efficacy and toxicity profiles compared to European populations. By integrating large-scale genomic data with longitudinal health outcomes, researchers are identifying novel biomarkers for early intervention strategies tailored to Asian genetic backgrounds. This population-focused approach represents a paradigm shift from one-size-fits-all medicine toward truly personalized healthcare. The implications extend beyond individual treatment optimization to public health planning for aging societies, particularly relevant as Asian populations experience rapid demographic transitions. While promising, the research highlights the ongoing challenge of translating population-level genetic insights into actionable clinical protocols, and the need for expanded diverse genomic databases to ensure precision medicine benefits reach all global populations equitably.